PUBLISHER: DelveInsight | PRODUCT CODE: 1048264
PUBLISHER: DelveInsight | PRODUCT CODE: 1048264
DelveInsight's, "VAP-1 Inhibitors- Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs based on VAP-1 Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
VAP-1 Inhibitors Understanding
VAP-1 Inhibitors: Overview
Vascular adhesion protein-1 (VAP-1) is an ectoenzyme that oxidates primary amines in a reaction producing also hydrogen peroxide. VAP-1 on the blood vessel endothelium regulates leukocyte extravasation from the blood into tissues under physiological and pathological conditions. Inhibition of VAP-1, also known as AOC3 protein inhibitors by neutralizing antibodies and by several novel small-molecule enzyme inhibitors interferes with leukocyte trafficking and alleviates inflammation in many experimental models. Targeting of VAP-1 also shows beneficial effects in several other diseases, such as ischemia/reperfusion, fibrosis, and cancer. Moreover, soluble VAP-1 levels may serve as a new prognostic biomarker in selected diseases.
VAP-1 Inhibitors Emerging Drugs Chapters
This segment of the VAP-1 Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
VAP-1 Inhibitors Emerging Drugs
TERN-201 is a potent SSAO inhibitor which provides an additional treatment mechanism for NASH by reducing oxidative stress and recruitment of white blood cells to the liver. TERN-201 is highly specific for SSAO, with a preferential in vitro selectivity index to SSAO over off-target monoamine oxidases (MAO) of >7,000-fold. Certain MAOs could be associated with potential drug-drug interactions in the NASH patient population. It is in phase I stage of development.
PRX167700 is a vascular adhesion protein-1 (VAP-1; AOC3) antagonist that is being developed by Proximagen (a subsidiary of BenevolentAI) for the treatment for Inflammatory pain. It is currently in phase II stage of development.
TT-01025 is a novel inhibitor of Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) for NASH. LG Chem Life Sciences and TransThera Biosciences jointly announced the Investigational New Drug (IND) application of TT-01025 has been submitted to Food and Drug Administration (FDA) in the United States.
Further product details are provided in the report……..
VAP-1 Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different VAP-1 Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 15+ key companies which are developing the therapies based on VAP-1 Inhibitors. The companies which have their drug candidate based on VAP-1 Inhibitors in the most advanced stage, i.e. phase II include Proximagen and others
DelveInsight's report covers around 15+ products under different phases of clinical development like
VAP-1 Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
VAP-1 Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses VAP-1 Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging VAP-1 Inhibitors drugs.
Key Questions
Key Players
Key Products
Introduction
Executive Summary
VAP-1 Inhibitors: Overview
Pipeline Therapeutics
Therapeutic Assessment
VAP-1 Inhibitors - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
VAP-1 Inhibitors Collaboration Deals
Late Stage Products (Phase III)
Drug Name: Company Name
Mid Stage Products (Phase II)
PRX 167700: Proximagen
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
TERN-201: Terns Pharmaceuticals
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
TT-01025: TransThera Biosciences
Inactive Products
VAP-1 Inhibitors Key Companies
VAP-1 Inhibitors Key Products
VAP-1 Inhibitors- Unmet Needs
VAP-1 Inhibitors- Market Drivers and Barriers
VAP-1 Inhibitors- Future Perspectives and Conclusion
VAP-1 Inhibitors Analyst Views
VAP-1 Inhibitors Key Companies
Appendix